Core Viewpoint - The company has received a regulatory decision from the Jilin Securities Regulatory Bureau, requiring it to rectify issues related to its governance and independence, particularly concerning its relationship with its controlling shareholder, Dongbao Group [1][2]. Group 1: Regulatory Decision and Company Response - The company has acknowledged the regulatory decision and has communicated it to relevant stakeholders, including its controlling shareholder and management [2]. - A board meeting was held to review and approve a rectification report in response to the regulatory decision [2]. Group 2: Identified Issues and Rectification Measures - The company and its controlling shareholder have been found to have overlapping property usage without formal rental agreements, indicating a lack of independence [3]. - To address this, the company signed a property lease agreement with Dongbao Group, specifying the rental terms for shared properties, ensuring market-based pricing for rent [4][5]. - The company will enhance training for its management and board members on compliance with relevant laws and regulations to improve operational standards [6]. Group 3: Rectification Status and Future Plans - The company has appointed specific individuals and departments responsible for the rectification process, and the measures have been completed [7]. - The company plans to maintain a focus on standardized governance and independence management in the long term [7]. - The regulatory inspection has provided valuable guidance for improving the company's governance level, and the company aims to strengthen its compliance and risk management systems [8].

智通财经记者 | 陈杨 智通财经编辑 | 谢欣 在行业媒体动脉网2018年的一篇报道中，天麦生物如此定位自己：在二代胰岛素上是跟随者，三代胰岛素上是竞争者，口服胰岛素上是引领者。 可以参考的是，同期，誉衡药业曾拟以不低于40亿元收购天麦生物不低于35%的可转让无负担股权，交易方亦承诺此后三年天麦生物净利润合计 达到18亿元。换而言之公司当时估值高达114亿元。不过该交易很快终止。 据天麦生物官网，2014年至2016年，公司先后完成二代胰岛素、三代（长效、速效）胰岛素类似物的开发、工艺放大及商业化规模的开发及生产 等工作。 智通财经注意到，当时，胰岛素确实是个好生意。据米内网数据，2016年，其在公立医疗机构终端市场规模约190亿元，诺和诺德、赛诺菲的单品 销售额约在25至35亿元，甘李药业、通化东宝单品销售额也各有13亿元。 而天麦生物更大的想象空间在于口服胰岛素。基于庞大的用药群体，这种让患者免于每天一针的给药方式的市场相当可观。 2015年，天麦生物与以色列Oramed公司签订投资协议及口服胰岛素大中华区技术许可协议。Oramed是一家以色列的纳斯达克上市公司。从公司名 上即可窥见，其致力于开发口服药物 ...

来源：市场资讯 （来源：动脉新医药） 也许正是看到天麦生物聚焦的巨大的糖尿病市场，以及其口服胰岛素可能带来的巨大突破，2016年，华 润医药与天麦生物签署战略合作协议并完成投资，但公开资料中未明确披露此次投资的具体金额。根据 后续公开信息，华润医药通过此次投资成为天麦生物重要股东，持股比例一度达20%。 但2017年底，华润医药将所持天麦生物14.12%股权以约11.47亿港元的公允价值出售。这一操作是基于 当时华润医药与天麦生物主要股东签订的股份认购协议中的相关条款，因天麦生物在2017年12月31日仍 未取得GMP证书，触发了股权出售条件。后续该股权通过产权交易所进行了公开转让程序。不过在 2020年，华润医药曾发文显示，还持有天麦生物23.75%股份，推测是其2017年出售股份后又增持了。 2月9日，华润医药公告，其全资附属公司华润医药投资已启动潜在出售华润医药投资及其附属公司所持 有天麦生物的约17.87%股权，其将通过上海联合产权交易所进行公开挂牌，挂牌底价约为人民币14.2亿 元。 天眼查数据显示，天麦生物股权结构较为多元，共涉及21家股东。其中，华润医药投资直接持有天麦生 物20%股权，实缴出资 ...

证券代码：600867 证券简称：通化东宝 公告编号：2026-013 通化东宝药业股份有限公司 关于对吉林证监局监督管理措施决定的整改报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 通化东宝药业股份有限公司（以下简称"公司"）于近日收到中国证券监督管理委 员会吉林监管局（以下简称"吉林证监局"）出具的《关于对通化东宝药业股份有限公 司采取责令改正并对李佳鸿采取出具警示函监督管理措施的决定》（吉证监决[2026]3 号)（以下简称"《决定书》"），要求公司就《决定书》中所提出的问题进行整改。 内容详见公司于2026年1月31日在上海证券交易所网站（www.sse.com.cn）披露的《关 于收到吉林证监局行政监管措施决定书的公告》（公告编号：2026-011）。 收到《决定书》后，公司及董事长高度重视，立即向控股股东东宝实业集团股份有 限公司（以下简称"东宝集团"）、公司董事、高级管理人员及相关部门负责人进行 通报和传达，对《决定书》中涉及的事项进行全面梳理和深入分析，严格遵照《公司 法》《证券法》《上市公司治理准则》《 ...

证券研究报告 行业周报 礼来替尔泊肽全线爆发，2025年合计贡献365亿美元 生物医药行业强于大市（维持） 平安证券研究所生物医药团队 分析师： 叶寅投资咨询资格编号:S1060514100001邮箱：YEYIN757@PINGAN.COM.CN 倪亦道投资咨询资格编号:S1060518070001邮箱：NIYIDAO242@PINGAN.COM.CN 韩盟盟投资咨询资格编号:S1060519060002邮箱：HANMENGMENG005@PINGAN.COM.CN 裴晓鹏投资咨询资格编号:S1060523090002邮箱：PEIXIAOPENG719@PINGAN.COM.CN 何敏秀投资咨询资格编号:S1060524030001邮箱：HEMINXIU894@PINGAN.COM.CN 王钰畅投资咨询资格编号:S1060524090001邮箱：WANGYUCHANG804@PINGAN.COM.CN 曹艳凯投资咨询资格编号:S1060524120001邮箱：CAOYANKAI947@PINGAN.COM.CN 张梦鸽投资咨询资格编号:S1060525070003邮箱：ZHANGMENGGE752@PINGA ...

Group 1: Market Overview - The global sales of GLP-1 drugs have surpassed Merck's Keytruda, with Eli Lilly's Tirzepatide generating $36.5 billion and Novo Nordisk's Semaglutide achieving $36.1 billion in 2025 [1] - The sales of Tirzepatide's weight loss indication increased by 175% year-on-year, while the diabetes indication grew by 99% [1] - The potential patient market for weight loss is significantly large, indicating a strong demand for GLP-1 drugs [1] Group 2: Company Developments - Several domestic companies, including Innovent Biologics, Jiangsu Hengrui Medicine, Tonghua Dongbao, and East China Pharmaceutical, are actively developing GLP-1 drugs to meet weight loss market demands [2] - Innovent Biologics' GLP-1 weight loss drug, Sema, has been approved for sale in China, contributing to the company's revenue growth, which is expected to exceed 10 billion yuan in 2025 [3] - Hengrui Medicine is developing HRS9531, which shows promising results in weight loss and blood sugar control, while also improving cardiovascular and renal risk factors [4] Group 3: Competitive Strategies - Companies are adopting differentiated strategies in drug development, such as creating oral formulations, extending drug half-lives, and innovating sales models [5] - Hengrui Medicine is focusing on developing a GLP-1/GIP dual receptor agonist, which aims to enhance efficacy and safety [5] - Tonghua Dongbao is also working on a GLP-1/GIP dual receptor agonist, with clinical trials progressing smoothly [5] Group 4: Research and Development Focus - Innovent Biologics is expanding its research pipeline to include long-acting, oral, and multi-target projects, aiming to provide more effective treatment options [6] - East China Pharmaceutical is developing an oral small molecule GLP-1 drug, with successful completion of all subject enrollments for its clinical phase III study in weight management [6]

Group 1 - The A-share tax refund store sector has shown a continuous rise, with Maoye Commercial reaching the daily limit increase [2] - Hangzhou Xie Bai previously hit the daily limit, while Bai Da Group increased by over 5% [2] - Other stocks such as Guangbai Co., Hebai Group, Yuyuan, Bailian Group, and New World also experienced gains [2]

Group 1 - A-shares opened lower and experienced significant adjustments, while the pharmaceutical sector showed resilience by performing well in the market [1] - The National Medical Products Administration announced on February 4 that during the 14th Five-Year Plan period, there will be strong support for the innovation and development of the biomanufacturing industry, transitioning the pharmaceutical industry from "follow-up innovation" to "systematic innovation" [1][3] - Analysts are optimistic about the Chinese medicine sector, expecting valuation recovery and performance improvement driven by policy support, cost improvements, and adjustments to the essential drug catalog [3] Group 2 - The raw material drug sector is viewed positively, with expectations of price recovery after several years of price declines, supported by rising prices of bulk commodities and upstream chemicals [3] - The medical ETF, the largest in the market, had a scale of 27.5 billion yuan as of February 3, 2026, indicating strong investor interest [3] - The pharmaceutical sector showed mixed performance, with innovative drug concepts mostly declining, while traditional Chinese medicine leaders like Darentang and Pizaihuang saw significant gains [5]

2月5日早盘，创新药概念股拉升，广生堂涨超13%，方盛制药、舒泰神、通化东宝、翰宇药业、盘龙药 业等涨幅居前。 ...

Core Viewpoint - The innovative drug ETF Tianhong (517380) has shown strong performance, with significant inflows and positive market reactions to earnings reports from key companies in the sector, particularly Eli Lilly's impressive revenue growth driven by weight loss drugs [2][3]. Group 1: ETF Performance - As of February 5, 2026, the innovative drug ETF Tianhong (517380) recorded a transaction volume of 4.9451 million yuan, with the tracked index HSSSHID rising by 0.11% [1]. - Over the past 20 trading days, the innovative drug ETF Tianhong (517380) attracted a total of 395 million yuan [2]. Group 2: Company Highlights - Eli Lilly reported a 43% year-over-year increase in Q4 revenue, reaching 19.29 billion dollars, with adjusted earnings per share of 7.54 dollars, both exceeding market expectations [2]. - Eli Lilly's weight loss drugs, Mounjaro and Zepbound, generated over 11.6 billion dollars in sales, accounting for more than 60% of total revenue [2]. - The company projects full-year revenue for 2026 to be between 80 billion and 83 billion dollars, with adjusted earnings per share expected to be between 33.50 and 35 dollars, also surpassing market forecasts [2]. Group 3: Industry Insights - Donghai Securities anticipates that the innovative drug sector will enter a phase of accelerated profit realization by 2025, with companies like Nocare and Rongchang Biopharma turning profitable [3]. - The core drivers of this growth are rapid commercialization of products and business development (BD) collaborations, with companies leveraging both to enhance profitability [3]. - The strong performance of the innovative drug sector validates the effectiveness of the domestic innovative drug business model, with core product commercialization supported by healthcare insurance being a fundamental growth driver [3].